GXE Stock Chart & Stats
€24.74
-€0.54(-1.96%)
At close: 4:00 PM EST
€24.74
-€0.54(-1.96%)
Day’s Range― - ―
52-Week Range€22.32 - €30.02
Previous CloseN/A
Volume150.00
Average Volume (3M)673.00
Market Cap
€1.86B
Enterprise Value-€394.90M
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.8
Beta0.37
Next Earnings
Nov 12, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume599
30 Day Avg. Volume673
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.95Price Target Upside0.85% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.53
Revenue Forecast (FY)€27.85M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetNear-zero leverage and a large equity base provide substantial financial resilience, reducing balance-sheet pressure while the company funds operations and investment. This conservative financial structure gives management greater flexibility to withstand volatility and pursue opportunities.
Profitability TurnaroundThe shift from losses in 2021–2022 to strong TTM profitability indicates a meaningful improvement in earnings power. If maintained, the high current margins can support reinvestment, strengthen returns on capital, and provide a more durable operating foundation.
High Gross MarginsConsistently high-90% gross margins point to an economically attractive revenue mix with substantial value retained after direct costs. That margin structure can support operating profitability and provide resilience if revenue growth becomes less consistent.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not currently self-funding, despite reported profitability. Continued cash burn can consume financial resources, increase reliance on the balance sheet, and constrain the company’s ability to invest or absorb setbacks.
Uneven Revenue MomentumThe TTM revenue decline following a sharp prior-year step-up shows that top-line momentum is not yet consistent. Uneven growth makes future earnings less predictable, complicates resource planning, and may limit the durability of recent profitability if contraction persists.
Earnings VolatilityHistorical earnings volatility makes current returns and margins less reliable as indicators of normalized performance. Variability can weaken forecasting confidence, complicate capital allocation, and increase the risk that recent improvements do not persist across future reporting periods.
Lakefront Biotherapeutics NV News
GXE FAQ
What was Lakefront Biotherapeutics NV’s price range in the past 12 months?
Lakefront Biotherapeutics NV lowest stock price was €22.32 and its highest was €30.02 in the past 12 months.
What is Lakefront Biotherapeutics NV’s market cap?
Lakefront Biotherapeutics NV’s market cap is €1.86B.
When is Lakefront Biotherapeutics NV’s upcoming earnings report date?
Lakefront Biotherapeutics NV’s upcoming earnings report date is Nov 12, 2026 which is in 16 days.
How were Lakefront Biotherapeutics NV’s earnings last quarter?
Lakefront Biotherapeutics NV released its earnings results on Aug 10, 2026. The company reported €0.03 earnings per share for the quarter, beating the consensus estimate of -€0.7 by €0.73.
Is Lakefront Biotherapeutics NV overvalued?
According to Wall Street analysts Lakefront Biotherapeutics NV’s price is currently Undervalued.
Does Lakefront Biotherapeutics NV pay dividends?
Lakefront Biotherapeutics NV does not currently pay dividends.
What is Lakefront Biotherapeutics NV’s EPS estimate?
Lakefront Biotherapeutics NV’s EPS estimate is -0.72.
How many shares outstanding does Lakefront Biotherapeutics NV have?
Lakefront Biotherapeutics NV has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics NV’s price movement after its last earnings report?
Lakefront Biotherapeutics NV reported an EPS of €0.03 in its last earnings report, beating expectations of -€0.7. Following the earnings report the stock price went up 4.284%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics NV?
Currently, no hedge funds are holding shares in DE:GXE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
GXE Stock 12 Month Forecast
Average Price Target
€24.95
▲(0.85% Upside)